SELP and Schnyder corneal dystrophy: Crizanlizumab is a monoclonal antibody that binds to P-selectin, blocking its interaction with glycoprotein ligand 1, which has been shown to play a pathogenic role in VOCs in SCD.5 Crizanlizumab is currently under investigation in a phase 2, open-label, single-arm, multicenter study to assess efficacy and safety in patients with SCD-related priapism (NCT03938454).6